Key facts
- Epigenica’s last known valuation is $3.8M (Oct 2023).
- It has raised $2.8M; the latest was Later Stage VC ($2.2M) in Jun 2025.
- Notable investors include Almi Invest, Swedish-American Chamber of Commerce - New York (SACCNY), DRIVE ( KI Innovations Business Incubator), EIT Health, Leksell Social Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Epigenica
- ·The full record, as it builds
Funding rounds
No funding rounds for Epigenica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epigenica
Operator of a life sciences technology company intended to provide innovations in epigenetic research. The company's platform enables researchers to perform comprehensive epigenetic studies at unprecedented speed, scalability, and affordability, offer comprehensive high-throughput profiling at different depths of detail with an array of possible starting materials, enabling researchers to advance biomedical research, drug discovery and development, precision medicine, diagnostics, and therapeutics for aging and longevity.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2020
- Employees
- 21
- Website
- epigenica.se/
- Ownership
- Privately Held (backing)
Epigenica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epigenica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epigenica in its N-PORT filings yet. We sweep new filings monthly.